Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is used in the treatment of several cancers, macular degeneration, and proliferative diabetic retinopathy as a means of limiting angiogenesis, a hallmark feature of these diseases. Nonspecific skin eruption has been reported in some patients receiving bevacizumab, and recently, bevacizumab-associated acneiform eruption was reported in the treatment of colon cancer (systemic administration) and macular degeneration (intravitreal administration).1-3 The eruption in these patients was strikingly similar to that characterized in patients treated with epidermal growth factor receptor (EGFR) inhibitors.1-4 We report a case of bevacizumab-induced acneiform eruption in a patient with glioblastoma multiforme.
Keenan BP, Abuav R. Acneiform Eruption in a Patient Receiving Bevacizumab for Glioblastoma Multiforme. Arch Dermatol. 2010;146(5):577. doi:10.1001/archdermatol.2010.68
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: